{"id":"W2766103705","doi":"10.1007/s41669-018-0112-1","title":"Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McGill University","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Pembrolizumab; Regimen; Internal medicine; Oncology; Progression-free survival; Cost effectiveness; Immunotherapy; Cancer; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002997006,0.001069847,0.0010982,0.00121393,0.000931222,0.002111476,0.001394508,0.0009284862,0.003034807],"category_scores_gemma":[0.008978849,0.0004583153,0.001727002,0.001813081,0.0006920106,0.0005757004,0.0009521654,0.001266951,0.0001043299],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.08331508,"about_ca_system_score_gemma":0.06650522,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9235267,"about_ca_topic_score_gemma":0.908836,"domain_scores_codex":[0.9980323,0.001014857,0.00006266383,0.0001099581,0.0003501139,0.0004300727],"domain_scores_gemma":[0.9967545,0.001352367,0.0003499015,0.00005904746,0.000952607,0.000531527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.01025602,0.00108546,0.05043305,0.002579409,0.003399335,0.0006445203,0.0001569908,0.8739789,0.0008397868,0.009136858,0.007369166,0.04012052],"study_design_scores_gemma":[0.005542472,0.003231251,0.04838433,0.0009891841,0.003820653,0.0003696038,0.0007931432,0.9216709,0.001052306,0.003005203,0.01098393,0.0001571183],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9252044,0.02120248,0.004682962,0.006718825,0.0001973534,0.00195745,0.01074155,0.00009973816,0.02919527],"genre_scores_gemma":[0.9939322,0.00197612,0.001405257,0.0002389584,0.0000160547,0.0001171611,0.001165244,0.000007045072,0.001142021],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08331508,"threshold_uncertainty_score":0.6044961,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02394847874053593,"score_gpt":0.3310521936035749,"score_spread":0.3071037148630389,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}